Across TCGA pan-cancer cohorts, OR2K2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated OR2K2 data layer compared with 13 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher OR2K2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR2K2 expression acts as an unfavorable survival marker.
SKCM are the cancer types where OR2K2 Mutation most reproducibly stratifies survival.